US stock · Healthcare sector · Drug Manufacturers—General

Gilead Sciences, Inc.

GILD

NASDAQ

77.09

USD

-0.56

(-0.72%)

Market Closed

17.23P/E

11Forward P/E

0.71P/E to S&P500

96.158BMarket CAP

3.79%Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

31 Jul-4 Aug

Shares Short

5/15/23

17.98M

Short % of Float

1.61%

Short % of Shares Outs.

1.44%

% Held by Insiders

0.10%

% Held by Institutions

85.97%

Beta

0.40

PEG Ratio

5.09

52w. high/low

89.74/57.17

Avg. Daily Volume

5.38M

Return %

Stock

S&P 500

1 year

19.76

2.11

3 years

2.05

38.05

5 years

14.26

54.53

Scale: |

High

Low

28.82

17.80

26.64

20.31

24.75

15.87

21.75

17.23

38.56

20.68

76.11

36.94

116.83

63.50

123.37

86.00

103.10

70.83

86.27

63.76

89.54

60.32

70.50

60.89

85.97

56.56

74.12

57.93

89.74

57.16

88.29

76.26

Currency: USD

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

2.28

2.90

3.88

4.64

5.41

6.41

7.33

16.35

22.29

22.70

19.97

17.05

17.68

19.64

21.74

28.75

Earnings per share

0.87

1.09

1.46

1.69

1.81

1.71

2.01

7.95

12.37

10.08

3.54

4.20

4.24

0.10

4.96

3.66

4.46

FCF per share

0.91

1.13

1.58

1.62

2.26

1.85

1.91

8.06

13.38

11.89

8.65

5.76

6.55

5.98

8.60

7.23

8.91

Dividends per share

- -

1.28

1.83

2.09

2.29

2.54

2.74

2.87

- -

3.97

CAPEX per share

0.04

0.06

0.13

0.04

0.09

0.26

0.12

0.37

0.51

0.56

0.45

0.71

0.65

0.52

0.46

- -

0.63

Book Value per sh.

1.86

2.26

3.52

3.42

4.35

6.15

7.44

10.14

12.66

14.11

15.64

16.48

17.74

14.48

16.77

- -

22.17

Comm.Shares outs.

1,858

1,841

1,809

1,712

1,550

1,515

1,529

1,522

1,464

1,339

1,307

1,298

1,270

1,257

1,256

1,255

941

Avg. annual P/E ratio

22.8

22.2

15.8

11.6

11.0

16.5

27.7

11.2

8.5

8.3

20.5

17.5

15.4

706.3

13.6

18.4

17.2

P/E to S&P500

1.3

1.0

0.2

0.6

0.7

1.1

1.6

0.6

0.4

0.9

0.7

0.6

18.7

0.5

0.9

0.7

Avg. annual div. yield

- -

1.2%

2.2%

2.9%

3.1%

3.9%

4.0%

4.3%

- -

5.2%

Revenue (m)

4,230

5,336

7,011

7,949

8,385

9,703

11,202

24,890

32,639

30,390

26,107

22,127

22,449

24,689

27,305

27,281

27,043

Operating margin

51.2%

50.2%

50.3%

49.8%

45.2%

41.3%

40.4%

61.3%

68.0%

58.0%

54.1%

37.1%

19.1%

16.5%

36.3%

26.9%

30.6%

Depreciation (m)

102

213

265

302

278

345

1,050

1,098

1,158

1,286

1,429

1,404

1,480

2,050

- -

1,252

Net profit (m)

1,615

2,011

2,636

2,901

2,804

2,592

3,075

12,101

18,108

13,501

4,628

5,455

5,386

123

6,225

4,592

5,583

Income tax rate

28.9%

26.5%

25.0%

26.2%

23.6%

28.7%

27.3%

18.8%

16.4%

21.1%

65.7%

30.0%

(4.0)%

94.7%

25.1%

21.5%

23.7%

Net profit margin

38.2%

37.7%

37.6%

36.5%

33.4%

26.7%

27.4%

48.6%

55.5%

44.4%

17.7%

24.7%

24.0%

0.5%

22.8%

16.8%

20.4%

Working capital (m)

2,292

3,079

2,941

3,243

11,404

1,886

948

11,953

14,872

11,226

20,188

25,231

20,537

4,599

3,162

15,227

3,844

Long-term debt (m)

1,312

1,356

1,243

2,946

7,606

7,055

3,939

11,921

21,195

26,346

30,795

24,574

22,094

28,645

25,179

- -

24,233

Equity (m)

3,460

4,152

6,367

5,864

6,739

9,310

11,369

15,426

18,534

18,887

20,442

21,387

22,525

18,202

21,069

- -

20,939

ROIC

32.6%

36.0%

34.9%

33.6%

20.2%

17.0%

20.8%

43.6%

45.2%

30.2%

8.6%

11.7%

12.4%

0.3%

12.4%

8.4%

12.4%

Return on capital

39.9%

40.2%

37.5%

35.6%

22.5%

19.0%

20.5%

44.7%

43.6%

32.0%

20.8%

14.0%

10.0%

3.9%

13.7%

10.7%

13.5%

Return on equity

46.7%

48.4%

41.4%

49.5%

41.6%

27.8%

27.0%

78.4%

97.7%

71.5%

22.6%

25.5%

23.9%

0.7%

29.5%

Infinity%

26.7%

Plowback ratio

100.0%

89.7%

81.8%

41.0%

45.5%

40.2%

(2,704.1)%

42.1%

- -

32.6%

Div.&Repurch./FCF

14.5%

82.5%

27.2%

137.1%

61.9%

7.2%

9.2%

40.9%

59.0%

83.2%

30.5%

74.7%

57.2%

63.5%

36.9%

- -

58.0%

Capital Structure

3 May · 2023 | Q1

All numbers in millions

Total liabilities

$ 40,937

Total assets

$ 61,876

Long-term debt

$ 24,233

Cash and equiv.

$ 4,936

Goodwill

$ 8,314

Retained earnings

$ 15,223

Common stock

- -

Enterprise Value

$ 115,455

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

7,408

6,520

- -

Receivables

4,892

4,493

4,777

Inventory

1,683

1,618

2,820

Other

2,013

1,482

1,633

Current assets

15,996

14,772

15,227

Acc. Payable

844

705

- -

Debt due

2,757

1,516

- -

Other

7,796

9,389

- -

Current liabilities

11,397

11,610

- -

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

(0.09)%

5.49%

15.45%

Cash flow

(16.04)%

7.33%

36.47%

Earnings

(26.23)%

1,208.94%

567.30%

Dividends

- -

Book value

- -

Insider Trading

Type

Date

Kramer Kelly A.

Award

1,887

05/03/23

Kramer Kelly A.

Award

10,173

05/03/23

Barton Jacqueline K

Award

1,887

05/03/23

Barton Jacqueline K

Award

10,173

05/03/23

Bluestone Jeffrey

Award

1,887

05/03/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

6,423

6,217

7,421

7,244

27,305

2022

6,590

6,260

7,042

7,389

27,281

2023

6,352

- -

Earnings per share

Currency: USD

Year

Total

2021

1.38

1.21

2.06

0.30

4.95

2022

0.01

0.91

1.43

1.31

3.65

2023

Infinity

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

0.73

0.71

0.72

0.71

2.87

2022

0.75

0.73

0.74

0.73

2.96

2023

Infinity

- -

Company Description

Sector:

Healthcare

Industry:

Drug Manufacturers—General

CEO:

Mr. Daniel P. O'Day

Full-time employees:

17,000

City:

Foster City

Address:

333 Lakeside Drive

IPO:

Jan 1, 1992

CIK:

0000882095

Website:

gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Powered by AI

Gilead Sciences, Inc.

77.09